Last reviewed · How we verify
influenza vaccination
Influenza vaccination stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
Influenza vaccination stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Prevention of seasonal influenza in adults and children, Reduction of influenza-related morbidity and mortality in high-risk populations.
At a glance
| Generic name | influenza vaccination |
|---|---|
| Also known as | Vaxigrip by Sanofi Pasteur, FluBlok, Fluzone, rHA, rHA0 |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral (antibody-mediated) and cell-mediated immune responses. This priming of the adaptive immune system enables rapid recognition and neutralization of wild-type influenza virus upon natural exposure, reducing infection risk and disease severity.
Approved indications
- Prevention of seasonal influenza in adults and children
- Reduction of influenza-related morbidity and mortality in high-risk populations
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Opioid, HIV and Immune System (PHASE4)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control (PHASE3)
- Influenza Immunization in Adults Over Age 75 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- influenza vaccination CI brief — competitive landscape report
- influenza vaccination updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI